Introduction to NDC 60429-0185
The National Drug Code (NDC) 60429-0185 corresponds to Enalapril Maleate, a medication manufactured and distributed by Golden State Medical Supply, Inc. Enalapril Maleate is an angiotensin-converting enzyme (ACE) inhibitor used primarily to treat high blood pressure and heart failure.
Current Market Status
As of the latest data, Enalapril Maleate with the NDC 60429-0185 is actively listed and available in the market. This drug is part of the extensive portfolio of medications supplied by Golden State Medical Supply, Inc., which includes a wide range of generic and branded pharmaceuticals[1].
Price Trends and Inflation
When analyzing the broader pharmaceutical market, it is crucial to consider the overall trends in drug pricing. According to Vizient's summer 2024 Pharmacy Market Outlook, the projected overall drug price inflation rate for 2025 is estimated at 3.81%. This inflation is driven by various factors, including the expanding indications of previously approved medications and the introduction of high-cost cell and gene therapies[3].
Specific Drug Pricing
While the Vizient report provides a general inflation rate, specific pricing for generic drugs like Enalapril Maleate can be more stable due to market competition. However, generic drug prices can still fluctuate based on factors such as raw material costs, manufacturing efficiencies, and regulatory changes.
Impact of Generic Competition
Enalapril Maleate, being a generic drug, is subject to competition from other generic manufacturers. This competition generally helps in keeping the prices relatively stable or even reducing them over time. However, any significant changes in the supply chain or regulatory environment could impact the pricing.
Regulatory and Reporting Requirements
For drugs like Enalapril Maleate, regulatory compliance is crucial. The Drug Name and NDC Reference Data provided by CMS ensures that all payments related to these drugs are accurately reported in the Open Payments system. This data is essential for maintaining transparency and compliance in the pharmaceutical industry[4].
Future Projections
Given the stable nature of generic drug markets and the absence of specific data indicating a significant price hike for Enalapril Maleate, it is reasonable to assume that the price of this drug will not deviate substantially from the general inflation rate projected by Vizient.
- Projected Price Inflation: For 2025, a modest increase in line with the overall drug price inflation rate of 3.81% is likely.
- Market Stability: The generic nature of Enalapril Maleate suggests that the market will remain relatively stable, with prices influenced more by general market conditions rather than specific drug-related factors.
Key Takeaways
- NDC 60429-0185 corresponds to Enalapril Maleate, an ACE inhibitor.
- Current Market Status: The drug is actively listed and available.
- Price Trends: Expected to follow the general drug price inflation rate of 3.81% for 2025.
- Regulatory Compliance: Adheres to CMS reporting requirements.
- Market Stability: Generic competition likely to maintain stable prices.
FAQs
Q: What is the NDC 60429-0185 used for?
A: The NDC 60429-0185 is used for Enalapril Maleate, an ACE inhibitor, primarily to treat high blood pressure and heart failure.
Q: What is the projected price inflation rate for this drug in 2025?
A: The projected price inflation rate for this drug is expected to be in line with the overall drug price inflation rate of 3.81% for 2025.
Q: Is Enalapril Maleate a generic or branded drug?
A: Enalapril Maleate is a generic drug.
Q: Who manufactures and distributes this drug?
A: Golden State Medical Supply, Inc. manufactures and distributes Enalapril Maleate with the NDC 60429-0185.
Q: What regulatory requirements does this drug need to comply with?
A: The drug needs to comply with CMS reporting requirements, including accurate reporting in the Open Payments system.
Cited Sources
- Find-A-Code: Golden State Medical Supply - NDC products.
- HealthData.gov: National Drug Code Directory.
- Vizient Inc.: Vizient projects drug price inflation at 3.81%.
- CMS: Drug Name and National Drug Code (NDC) Reference Data Instructions.
- Vizient Inc.: Pharmacy Market Outlook Summer 2024.
